Performance of Qualitative and Quantitative Antigen Tests for SARS-CoV-2 Using Saliva

Yokota, Isao; Sakurazawa, Takayo; Sugita, Junichi; Iwasaki, Sumio; Yasuda, Keiko; Yamashita, Naoki; Fujisawa, Shinichi; Nishida, Mutsumi; Konno, Satoshi; Teshima, Takanori

Performance of Qualitative and Quantitative Antigen Tests for SARS-CoV-2 Using Saliva

Yokota, Isao; Sakurazawa, Takayo; Sugita, Junichi et al.

Infectious Disease Reports, 2021, 13(3), 742-747

Permalink : https://hdl.handle.net/2115/83161

このアイテムのアクセス数:458件（2026-08-13 15:57 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.3390/idr13030069			41

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/83161
タイトル	Performance of Qualitative and Quantitative Antigen Tests for SARS-CoV-2 Using Saliva
著者	Yokota, Isao ; Sakurazawa, Takayo ; Sugita, Junichi ; Iwasaki, Sumio ; Yasuda, Keiko ; Yamashita, Naoki ; Fujisawa, Shinichi ; Nishida, Mutsumi ; Konno, Satoshi ; Teshima, Takanori
e-Rad_Researcher 20761414 著者名 Yokota, Isao
著者名 Sakurazawa, Takayo
e-Rad_Researcher 70755694 著者名 Sugita, Junichi
著者名 Iwasaki, Sumio
著者名 Yasuda, Keiko
著者名 Yamashita, Naoki
著者名 Fujisawa, Shinichi
e-Rad_Researcher 90404722 著者名 Nishida, Mutsumi
e-Rad_Researcher 20399835 著者名 Konno, Satoshi
e-Rad_Researcher 40284096 著者名 Teshima, Takanori
言語	英語
キーワード	SARS-CoV-2
	COVID-19
	saliva
	Lumipulse
	Espline
	ICA
	CLEIA
発行日	2021-09
出版者	MDPI
収録物名	Infectious Disease Reports
巻(号)	13(3)
ページ	742-747
抄録	The rapid detection of SARS-CoV-2 is critical for the prevention of disease outbreaks. Antigen tests such as immunochromatographic assay (ICA) and chemiluminescent enzyme immunoassay (CLEIA) can yield results more quickly than PCR. We evaluated the performance of ICA and CLEIA using 34 frozen PCR-positive (17 saliva samples and 17 nasopharyngeal swabs [NPS]) and 309 PCR-negative samples. ICA detected SARS-CoV-2 in only 14 (41%) samples, with positivity rates of 24% in saliva and 59% in NPS. Notably, ICA detected SARS-CoV-2 in 5 of 6 samples collected within 4 days after symptom onset. CLEIA detected SARS-CoV-2 in 31 (91%) samples, with a positivity of 82% in saliva and 100% in NPS. These results suggest that the use of ICA should be limited to an earlier time after symptom onset and CLEIA is more sensitive and can be used in situations where quick results are required.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	2036-7430
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.3390/idr13030069